recombinant anti-HER2 structural domain II/IV bispecific antibody (Xuanzhu Pharma)

N/A

Report date: 2025/03/20 09:38:25

Base Information

Drug Namerecombinant anti-HER2 structural domain II/IV bispecific antibody (Xuanzhu Pharma)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesXuanzhu Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXuanzhu Pharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A